title: The development and manufacture of influenza vaccines.
abstract: The development and manufacture of an Influenza vaccine is unlike any other product in the Vaccine industry because of the need to change composition on a yearly basis. The poor efficacy of Influenza vaccines over the past 2 y in the Northern Hemisphere invites questions on how the vaccines are manufactured and how change in vaccine composition is controlled. The opinion expressed in this commentary is that the risk of not making the correct HA protein is increased by the need to adapt the new seasonal virus for good propagation in embryonated chicken eggs. This adaptation is required because not enough doses can be made in time for the new 'flu season unless productivity is reasonable. This problem is not necessarily solved by going to a cell culture host for virus propagation and that may explain why this more advanced technology approach is not more widely used. A vaccine based on hemagglutinin (HA) protein that does not involve Influenza virus propagation (such as Flublok®) side steps this particular problem. The exact HA sequence can be used as is in the virus. The technology can be run at large scale, already at 2 × 21,000L in Japan, in contrast to eggs where scale-up is by multiplication; the HA product is highly purified and made consistently in the form of rosettes.
authors.affiliation: a University College London ; London , UK.
authors.forename: Barry C
authors.initials: BC
authors.lastname: Buckland
mesh_terms: D000818:Animals; D001709:Biotechnology / Q000379:methods*; D006801:Humans; D007252:Influenza Vaccines / Q000302:isolation & purification*; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D007252:Influenza Vaccines
keywords: Flublok®; hemagglutinin; influenza; vaccine manufacturing
references.citation: PLoS One. 2014;9(3):e92153
references.pmid: 24667168
references.citation: Vaccine. 2011 Jul 1;29 Suppl 1:A2-7
references.pmid: 21684422
references.citation: Vaccine. 2014 Sep 22;32(42):5496-502
references.pmid: 25131727
references.citation: J Invertebr Pathol. 2011 Jul;107 Suppl:S31-41
references.pmid: 21784229
references.citation: Perm J. 2007 Summer;11(3):63-9
references.pmid: 21461116
references.citation: Biotechnol Bioeng. 2012 Jun;109(6):1443-60
references.pmid: 22407777
references.citation: Vaccine. 2011 Oct 13;29(44):7733-9
references.pmid: 21835220